Clinafloxacin and trovafloxacin are two new fluoroquinolones for which few comparative data are available. When MICs of ciprofloxacin against Gram-positive and Gram-negative nosocomial species were compared, clinafloxacin was the most potent although trovafloxacin was also more active than ciprofloxacin against Staphylococcus aureus and enterococci. All three drugs were bactericidal. Clinafloxacin displayed the lowest frequency of resistance, approximating 10 11 . Development of resistance studies over 13-14 passages in the presence of drug revealed a 32-fold increase in MIC of clinafloxacin against S. aureus compared with 512-and 1024-fold for trovafloxacin and ciprofloxacin respectively, although the three drugs were comparable against Enterococcus faecalis and the Gram-negative bacilli.
Introduction
Clinafloxacin (CLX; CI-960; PD 127391) and trovafloxacin (CP 99,219) are fluoroquinolones (Figure) in late stage clinical development which have attracted much attention because of their high potency and broad spectrum. Both drugs have been reported to possess excellent in-vitro activity against Streptococcus pneumoniae, 1,2 and clinafloxacin has been shown to be more active against some isolates of vancomycin-resistant enterococci. 3 Comparison of their in-vitro antibacterial activities against other species are confounded by the paucity of side-by-side test reports. We have tested these drugs and ciprofloxacin by microbroth dilution following NCCLS guidelines against a battery of nosocomial pathogens. 
Materials and methods

Bacterial strains
A total of 211 Gram-positive and -negative bacterial strains was tested including recent clinical isolates, American Type Culture Collection reference strains, and cultures from the Parke-Davis culture collection.
Susceptibility testing
Tests for MICs and MBCs followed current NCCLS guidelines for broth and agar (Difco, Detroit, MI, USA) dilutions employing cation-adjusted Mueller-Hinton (CAMHB) and Anaerobe Broth MIC media with incubations at 35°C.
Resistance studies
Frequency of single-step drug-resistant spontaneous mutants was determined by spreading ~10 11 cfu in 250 L aliquots on to Mueller-Hinton agar containing drug at concentrations of four-, eight-, and 16-fold MICs. After 24-72 h incubation, resistant colonies were confirmed by replica plating. The resistance frequency was calculated as the number of resistant colonies per inoculum.
Multi-step resistance selection measured increases in MICs obtained from tube dilutions in 5 mL. Each tube was inoculated with a 0.1 mL aliquot harvested from the previous test's highest concentration of drug that permitted growth virtually equal to the drug-free control tube. The process was performed for up to 14 daily transfers.
Results and discussion
In-vitro susceptibility
Clinafloxacin and trovafloxacin inhibitory activities (Table  I) were within a two-fold microbroth MIC range against Enterococcus faecalis (MIC 90 s 0.125 and 0.25 mg/L, respectively) and oxacillin-resistant Staphylococcus aureus (ORSA; MIC 90 s 0.03 mg/L). Clinafloxacin showed up to four-fold greater activity than trovafloxacin against occasional isolates of Enterococcus faecium (MIC 90 s 0.5 and 2 mg/L, respectively), and ciprofloxacin-resistant E. faecium, E. faecalis and ORSAs. Enterococcal susceptibilities to each fluoroquinolone were unaffected by resistance to vancomycin although other workers 3 have reported that the order of activity against vancomycin-resistant enterococci is clinafloxacin > trovafloxacin > ciprofloxacin.
Ciprofloxacin MICs for these isolates relative to clinafloxacin were generally 16-fold greater for ORSA and 32-to 128-fold greater for ciprofloxacin-resistant ORSA (the highest MICs measured for these staphylococci were 128 mg/L of ciprofloxacin and 2 mg/L of clinafloxacin); eight-to 16-fold greater for E. faecalis, and ciprofloxacin-resistant E. faecalis and E. faecium; and four-to eight-fold greater for E. faecium.
Against both enteric and oxidative Gram-negative bacteria clinafloxacin MICs were consistently lower than those of trovafloxacin, four-to eight-fold against Klebsiella pneumoniae (MIC 90 0.06 mg/L), four-to 32-fold against Serratia marcescens (MIC 90 0.125 mg/L), two-to 16-fold against Pseudomonas aeruginosa (MIC 90 0.5 mg/L), two-to eight-fold against Burkholderia cepacia ( M I C 9 0 4 mg/L), and two-to four-fold against Stenotrophomonas maltophilia ( M I C 9 0 0.5 mg/L). Ciprofloxacin MICs for these same isolates relative to clinafloxacin were generally two-to four-fold greater against K. pneumoniae, S. marcescens, P. aeruginosa, and B. cepacia, and 16-fold greater against S. maltophilia.
For anaerobes, clinafloxacin (MIC 90 0.25 mg/L) MICs were two-to four-fold lower than trovafloxacin for Bacteroides fragilis, and clinafloxacin (MIC 90 2 mg/L) MICs were four-to eight-fold lower than trovafloxacin values for Clostridium difficile. Ciprofloxacin MICs against these same isolates relative to clinafloxacin were 16-to 64-fold higher against both B. fragilis and C. difficile.
As noted in an earlier study, 4 no cross resistance between fluoroquinolones and other drug classes was demonstrated.
All three fluoroquinolones were bactericidal for S. aureus UC-76, E. faecalis MGH-2, Eschericia coli Vogel, K. pneumoniae MGH-2, S. marcescens IMM-16, and P. aeruginosa IM-1 (Table II) . 
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Resistance studies
Testing for frequency of spontaneous (single-step) resistance at four times MIC for strains of S. aureus, E. faecalis, E. coli, K. pneumoniae, and S. marcescens demonstrated that (Table III) clinafloxacin resistance was low and undetectable (less than 1 in 10 11 ) compared with trovafloxacin frequencies of 7.9 10 8 against K. pneumoniae and 2.6 10 7 against S. marcescens, and ciprofloxacin values of 1.7 10 10 against K. pneumoniae and 6.9 10 10 against E. coli. Our results for S. aureus agree with those reported by Barry et al., 5 where first step resistant cells were detected at four times MIC for ciprofloxacin but not trovafloxacin. Although clinafloxacin-resistant cells were detectable (at a frequency of 4.3 10 9 ) against P. aeruinosa, resistance frequencies were greater against this organism for trovafloxacin (4.1 10 7 ) and for ciprofloxacin (1.6 10 8 ). Comparative data are also displayed for streptomycin, a drug used frequently as an indicator of bacterial resistance.
Development of resistance to fluoroquinolones in these same strains was stepwise when monitored during 13-14 passages in subinhibitory concentrations of drug (Tables   210   Table IV . Macrobroth MICs (in mg/L) for cultures obtained from 13-passage multi-step resistance studies of S. aureus UC-76 In multi-step resistance studies against the other species, the three drugs' performances were comparable (within a four-fold range), although clinafloxacin consistently displayed the lowest MICs, and trovafloxacin end (passage 14) MICs exceeded that drug's proposed 3 susceptible breakpoint ( 2 mg/L).
Clinafloxacin was the most active drug among the three fluoroquinolones tested. Trovafloxacin was more active than ciprofloxacin against staphylococci and enterococci, and these two drugs were comparable overall against the Gram-negative species tested. All three agents were bactericidal. As with other fluoroquinolones, the frequency of single-step resistance was low for clinafloxacin, trovafloxacin, and ciprofloxacin against the nonfastidious aerobic species tested, although somewhat higher frequencies were measured for trovafloxacin and ciprofloxacin against some Gram-negative species. Also, the three drugs were comparable in multi-step MIC increases against fluoroquinolone-selected mutants of E. faecalis and Gram-negative species, although the increases in MICs against S. aureus were in the order clinafloxacin < trovafloxacin < ciprofloxacin. Our results indicate that clinafloxacin and trovafloxacin are both highly active in vitro, but their clinical potentials will need to be confirmed in human trials.
